Over 2 million patients annually are unable to communicate due to non-invasive ventilation (NIV). Ataia Medical is dedicated to introducing innovative technology to allow patients to verbally communicate with their new communication system, SPEAX.
SPEAX can be adhered to the outside of hospital NIV mask without interrupting patients' life saving therapy.
In out of clinic validation, SPEAX improved intelligibility of participants undergoing NIV by 386%.
Patients that are unable to communicate are 3x more likely to experience a preventable adverse event.
This patented flagship product from Ataia Medical allows NIV patients to verbally communicate with their care team and loved ones. This two part system is comprised of a disposable Patch that can be adhered to the outside of virtually any NIV mask and a reusable Communicator that amplifies the patient's voice through a built in speaker.
Chief Executive officer
Chief operational officer
Chief marketing officer
Chief Medical officer
Ataia Medical presented at the BIOTECH Showcase during the JP Morgan Healthcare Conference in San Fransico on January 9th.
Ataia Medical has raised a seed funding round of $300,000. Investors include medical-specific firm Green Park and Golf, as well as angel investors that specialize in medical devices.
Ataia Medical CEO, Tyler Register, presented at the Majestic Theater in Dallas, TX. His presentation expands on the issues surrounding communication with NIV patients and Ataia Medical's solution.
Ataia Medical joined the Fall 2017 cohort of the Health Wildcatters Accelerator. Health Wildcatters is a Dallas-based, mentor driven, healthcare seed-fund accelerator that offers a 12-week program for start-ups that focus on health-related innovations.
Sign-up to receive our monthly newsletter.
Please leave your email bellow and select your interest.
1910 Pacific Avenue #20 000 • Dallas, TX